Moderna shares have more than doubled in price, posting a 127% surge that has investors asking whether the stock still has room to run or whether the market has already priced in the news driving that move.
What Pushed Moderna This High
The rally centers almost entirely on Moderna’s mRNA-based cancer vaccine program, which has captured enormous attention from retail and institutional investors alike. mRNA technology, the same platform behind Moderna’s COVID-19 vaccine, is now being tested as a way to train the immune system to attack cancer cells – a concept that has generated significant scientific and financial excitement.
Moderna’s cancer vaccine work is being developed in partnership with Merck. The two companies are jointly developing mV-4463, a personalized cancer vaccine that uses mRNA to target the specific mutations found in an individual patient’s tumor. Early clinical data from melanoma trials has shown meaningful improvement in recurrence-free survival when the vaccine is added to Keytruda, Merck’s blockbuster immunotherapy drug. That data point, more than anything else, explains the stock’s trajectory over the past several months.
Personalized cancer vaccines are not a simple product to manufacture or scale. Each dose is custom-built based on genomic sequencing of the patient’s tumor, meaning the supply chain, cost structure, and production timelines look nothing like a traditional pharmaceutical rollout. That complexity is part of what makes the upside so large – and the execution risk so real.
Moderna is not yet profitable. The company generated massive revenue during the COVID-19 pandemic, but those numbers have fallen sharply as booster demand declined. The cancer vaccine program is still in clinical trials, generating no commercial revenue. Investors buying Moderna today are making a bet on a product that does not yet exist in commercial form, priced as though it already does.
Why the Valuation Is the Problem
A 127% gain is not inherently a reason to avoid a stock. Plenty of biotechs have doubled and then doubled again when the underlying science validated. The question for Moderna is whether the current share price still reflects a reasonable margin of safety, or whether the market has already assigned full credit for an outcome that remains years and several regulatory hurdles away.
Biotech valuations under these conditions rely heavily on probability-weighted assessments of approval likelihood, market size, pricing power, and competitive positioning. For a personalized cancer vaccine targeting melanoma recurrence, each of those variables carries meaningful uncertainty. Melanoma is a relatively small patient population compared to the addressable markets that typically justify the scale of Moderna’s current market capitalization. Expanding the program to lung, bladder, or colorectal cancers – which Merck and Moderna are actively pursuing – would dramatically change the commercial math, but those trials are at earlier stages.
The competitive landscape adds another layer of pressure. BioNTech, which co-developed the Pfizer COVID-19 vaccine, is running a parallel mRNA cancer vaccine program with its own personalized approach. Early BioNTech data has also looked promising in melanoma. If two well-funded companies are racing toward the same therapeutic concept with comparable technology, the first-mover advantage that typically justifies a premium valuation becomes harder to sustain.
Moderna’s cash position matters here too. After the COVID revenue peak, the company has been burning through reserves to fund its pipeline. R&D spending on the cancer vaccine program is substantial, and the company has been managing its cost structure carefully to extend its runway. Any delay in the cancer vaccine timeline – a failed phase 3 endpoint, a safety signal, a manufacturing setback – would hit the stock hard precisely because so much of the current price reflects expectations for that program specifically.
There is also the regulatory path to consider. The FDA has granted Breakthrough Therapy designation to the mRNA-4157/V940 program, which is the clinical name for the Moderna-Merck personalized cancer vaccine. That designation is meaningful – it allows for more intensive FDA guidance during development and is associated with faster review timelines. But Breakthrough Therapy designation does not guarantee approval, and it does not compress the clinical timeline enough to change the fundamental calculus that investors buying at today’s prices are paying for outcomes that are still 2-3 years from potential commercialization at minimum.
Moderna’s COVID-19 vaccine franchise, meanwhile, continues to generate some revenue through annual booster cycles, but that market has stabilized at a fraction of its pandemic peak. The respiratory syncytial virus (RSV) vaccine program and the flu combination vaccine candidates in Moderna’s pipeline represent additional potential revenue streams, but those products face established competition and are unlikely to move the needle the way a successful cancer vaccine approval would.
What a Buyer Is Actually Accepting Today
Buying Moderna after a 127% gain means accepting that the mRNA cancer vaccine succeeds in later-stage trials, clears the FDA, achieves meaningful commercial uptake in an entirely new manufacturing and distribution model, and does so before the company’s financial reserves create additional pressure. That is not an impossible scenario – the science is genuinely promising, and the Merck partnership provides both capital and commercial infrastructure that Moderna could not build alone. But each of those conditions needs to hold, and the stock’s current price leaves little room for any of them to disappoint.
The FDA’s Breakthrough Therapy designation, the Merck partnership structure, the early melanoma trial results – none of those facts have changed since the stock was trading at half its current price. What has changed is how much investors are now paying for those same facts.
